생물정신의학 (Korean Journal of Biological Psychiatry)
- 제3권2호
- /
- Pages.277-287
- /
- 1996
- /
- 1225-8709(pISSN)
- /
- 2005-7571(eISSN)
주정중독에 동반된 우울증의 치료에서 Paroxetine과 Amitriptyline의 이중맹 비교 : 치료초기 2주 동안의 행동학적 부작용
A Double-Blind Comparison of Paroxetine and Amitriptyline in the Treatment of Depression Accompanied by Alcoholism : Behavioral Side Effects during the First 2 Weeks of Treatment
-
윤진상
(전남대학교 의과대학 신경정신과학교실) ;
- 윤보현 (국립나주정신병원) ;
- 최태석 (국립나주정신병원) ;
- 김용범 (국립나주정신병원) ;
-
이형영
(전남대학교 의과대학 신경정신과학교실)
-
Yoon, Jin-Sang
(Department of Neuropsychiatry, College of Medicine, Chonnam National University) ;
- Yoon, Bo-Hyun (Naju National Mental Hospital) ;
- Choi, Tae-Seok (Naju National Mental Hospital) ;
- Kim, Yong-Bum (Naju National Mental Hospital) ;
-
Lee, Hyung-Yung
(Department of Neuropsychiatry, College of Medicine, Chonnam National University)
- 발행 : 1996.12.25
초록
본 연구는 주정중독에 동반된 우울증 환자의 치료에서 적어도 행동학적 부작용의 관점에서는 PAR이 AMI보다 우수함을 증명하였다. 이러한 PAR의 행동학적 효과의 우수성은 환자의 삶의 질을 향상시키고 결국 치료결과를 높이는데 관여하리라고 생각된다.
Objective : It has been proposed that cognition and related aspects of mental functioning are decreased in depression as well as in alcoholism. The objective of the study was to compare behavioral side effects of paroxetine and amitriptyline in depressed patients accompanied by alcoholism. The focused comparisons were drug effects concerning psychomotor performance, cognitive function, sleep and daytime sleepiness during the first 2 weeks of treatment. Methods : After an alcohol detoxification period(3 weeks) and a washout period(1 week), a total of 20 male inpatients with alcohol use disorder (DSM-IV), who also had a major depressive episode(DSM-IV), were treated double-blind with paroxetine 20mg/day(n=10) or amitriptyline 25mg/day(n=10) for 2 weeks. All patients were required to have a scare of at least 18 respectively on bath the Hamilton Rating Scale far Depression(HAM-D) and Beck Depression Inventory(BDI) at pre-drug baseline. Patients randomized to paroxetine received active medication in the morning and placebo in the evening whereas those randomized to amitriptyline received active medication in the evening and placebo in the morning. All patients performed the various tasks in a test battery at baseline and at days 3, 7 and 14. The test battery included : critical flicker fusion threshold for sensory information processing capacity : choice reaction time for gross psychomotor performance : tracking accuracy and latency of response to peripheral stimulus as a measure of line sensorimotor co-ordination and divided attention : digit symbol substitution as a measure of sustained attention and concentration. To rate perceived sleep and daytime sleepiness, 10cm line Visual analogue scales were employed at baseline and at days 3, 7 and 14. The subjective rating scales were adapted far this study from Leeds sleep Evaluation Questionnaire and Epworth Sleepiness Scale. In addition a comprehensive side effect assessment, using the UKU side effect rating scale, was carried out at baseline and at days 7 and 14. The efficacy of treatment was evaluated using HAM-D, BDI and clinical global impression far severity and improvement at days 7 and 14. Results : The pattern of results indicated thai paroxetine improved performance an mast of the lest variables and also improved sleep with no effect on daytime sleepiness aver the study period. In contrast, amitriptyline produced disruption of performance on same tests and improved sleep with increased daytime sleepiness in particular at day 3. On the UKU side effect rating scale, mare side effects were registered an amitriptyline. The therapeutic efficacy was observed in favor of paroxetine early in day 7. Conclusion : These results demonstrated thai paroxetine in much better than amitriptyline for the treatment of depressed patients accompained by alcoholism at least in terms of behavioral safety and tolerability, furthermore the results may assist in explaining the therapeutic outcome of paroxetine. For example, and earlier onset of antidepressant action of paroxetine may be caused by early improved cognitive function or by contributing to good compliance with treatment.
키워드